PROTACs: A Paradigm Shift in Drug Discovery – Module 3

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (3 of 5 Modules)

This activity provides an overview of emerging data in the development of proteolysis targeting chimeras (PROTACs) that harness intracellular E3-ubiquitin ligases for the treatment of hematologic malignancies.

0.50 CE Credit(s)
Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies

Activity Faculty

Donovan, Katherine-Faculty Headshot-135x135

Katherine Donovan, PhD

Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources